Novavax Updates FY23 Revenue Guidance To $1.3B-$1.5B Compared to Prior Guidance Of $1.4B-$1.6B And Consensus Of $1.44B
Portfolio Pulse from Benzinga Newsdesk
Novavax has updated its FY23 revenue guidance to $1.3B-$1.5B, a decrease from the previous guidance of $1.4B-$1.6B. This is also below the consensus estimate of $1.44B.
August 08, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Novavax's updated FY23 revenue guidance is lower than previously estimated, which could negatively impact the company's stock price in the short term.
Novavax's updated revenue guidance is lower than both its previous guidance and the consensus estimate. This could lead to a negative market reaction, potentially driving the stock price down in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100